CA2900454A1 - Pharmaceutical compositions comprising vesicles - Google Patents

Pharmaceutical compositions comprising vesicles Download PDF

Info

Publication number
CA2900454A1
CA2900454A1 CA2900454A CA2900454A CA2900454A1 CA 2900454 A1 CA2900454 A1 CA 2900454A1 CA 2900454 A CA2900454 A CA 2900454A CA 2900454 A CA2900454 A CA 2900454A CA 2900454 A1 CA2900454 A1 CA 2900454A1
Authority
CA
Canada
Prior art keywords
vesicle
animal
vesicles
composition
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2900454A
Other languages
English (en)
French (fr)
Inventor
Guido Grandi
Alberto Grandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Externautics SpA
Original Assignee
GlaxoSmithKline Biologicals SA
Externautics SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, Externautics SpA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA2900454A1 publication Critical patent/CA2900454A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
CA2900454A 2013-02-07 2014-02-06 Pharmaceutical compositions comprising vesicles Abandoned CA2900454A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13154463 2013-02-07
EP13154463.7 2013-02-07
PCT/EP2014/052370 WO2014122232A1 (en) 2013-02-07 2014-02-06 Pharmaceutical compositions comprising vesicles

Publications (1)

Publication Number Publication Date
CA2900454A1 true CA2900454A1 (en) 2014-08-14

Family

ID=47681775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900454A Abandoned CA2900454A1 (en) 2013-02-07 2014-02-06 Pharmaceutical compositions comprising vesicles

Country Status (7)

Country Link
US (1) US20160120818A1 (https=)
EP (1) EP2953620A1 (https=)
JP (1) JP2016507543A (https=)
CN (1) CN105163724A (https=)
BR (1) BR112015018877A2 (https=)
CA (1) CA2900454A1 (https=)
WO (1) WO2014122232A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037503B1 (ru) * 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
CN106999444B (zh) * 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
US20190091307A1 (en) * 2016-03-03 2019-03-28 Institut Gustave Roussy Ptps-based vaccines against cancer
EP3563835A4 (en) * 2016-12-29 2020-12-30 Korea Institute of Science and Technology NEW EXOSOME-BASED ANTI-CANCER AGENT
US11524037B2 (en) 2017-09-08 2022-12-13 Evelo Biosciences, Inc. Bacterial extracellular vesicles
BR102018008194A2 (pt) * 2018-04-24 2020-07-07 Universidade De São Paulo - Usp. kit farmacêutico e seus usos
WO2019210189A1 (en) * 2018-04-26 2019-10-31 University Of Louisville Research Foundation, Inc. Edible plant exosome-like nanovectors for vaccination
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020146390A1 (en) * 2019-01-09 2020-07-16 Exocure Biosciences, Inc. Bacteria-derived vesicles and uses thereof
CN110367202B (zh) * 2019-06-20 2021-11-02 广东医科大学附属医院 一种肠菌外膜囊泡在制备痴呆动物模型中的应用
US20220378902A1 (en) * 2019-08-22 2022-12-01 Sichuan University Bacterial membrane vesicles, and separation and preparation system and method therefor
EP4013392B1 (en) 2019-09-13 2026-04-29 Exocure Sweden AB Use of ghost nanovesicles as therapeutics
CN111521826A (zh) * 2020-05-21 2020-08-11 江海松 外周血外泌体中Notch3蛋白作为分子标记的应用及一种检测试剂盒
WO2022154149A1 (ko) * 2021-01-14 2022-07-21 (주)엑솔런스 세포외소포체를 이용한 백신 조성물
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
KR20240010702A (ko) * 2022-07-13 2024-01-24 (주)엑솔런스 항원 단백질 또는 상기 단백질을 암호화하는 유전자를포함하는 세포외소포체 및 그의 용도
CN115350161B (zh) * 2022-08-19 2024-04-16 沈阳药科大学 基于工程化益生菌外膜囊泡包被纳米酶递送系统及其制备方法和应用
CN117065041B (zh) * 2023-04-04 2024-02-27 山东大学 一种包被载药脂质纳米粒的外膜囊泡及其制备方法和应用
CN120789140B (zh) * 2025-09-12 2026-04-10 湖北医药学院 一种治疗结肠炎的联合用药物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
EP1718338B1 (en) * 2004-02-02 2015-05-06 EnGeneIC Molecular Delivery Pty Ltd. Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
CN102014934B (zh) * 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
JP5667180B2 (ja) * 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles

Also Published As

Publication number Publication date
JP2016507543A (ja) 2016-03-10
US20160120818A1 (en) 2016-05-05
WO2014122232A1 (en) 2014-08-14
EP2953620A1 (en) 2015-12-16
BR112015018877A2 (pt) 2017-08-22
CN105163724A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
US20160120818A1 (en) Pharmaceutical compositions comprising vesicles
JP7812573B2 (ja) 生体高分子薬を送達するための組成物及び方法
JP7730867B2 (ja) 結合エピトープを含有する融合タンパク質を封入する粒子
Christensen et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
JP2024028876A (ja) 免疫応答を調節可能な金属含有製剤のための組成物および方法
Shariat et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer
Gómez et al. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis
US20200405835A1 (en) Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypetides and immunogenic compositions thereof
RU2578420C2 (ru) Иммуностимулирующие и вакцинные композиции
Rostami et al. Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: A preliminary study
JP6487850B2 (ja) アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法
Moore et al. Injectable, ribbon-like microconfetti biopolymer platform for vaccine applications
Kumar et al. Development of soluble inulin microparticles as a potent and safe vaccine adjuvant and delivery system
Granadillo et al. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice
Wang et al. The mechanism of action of acid-soluble chitosan as an adjuvant in the formulation of nasally administered vaccine against HBV
Yan et al. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome
Arias et al. Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen
Jahan et al. Potentiating antigen specific immune response by targeted delivery of the PLGA-based model cancer vaccine
Wang et al. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells
Blom et al. Virosome-bound antigen enhances DC-dependent specific CD4+ T cell stimulation, inducing a Th1 and Treg profile in vitro
Hu et al. Toll-like receptor 9 agonists as adjuvants for nanoparticle-based nicotine vaccine
Tiwari et al. Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen
Kuai et al. Lipid-based nanoparticles for vaccine applications
Pan et al. Nanoadjuvant‐Mediated EV‐Derived Artificial APC to Trigger Protective Immunity Against Virus Infection

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200206